FDA recommends against seven peptides including BPC-157 and TB-500, dealing major blow to gray market

FDA Recommends Against Seven Peptides, Effectively Banning Gray Market

The FDA recommended against adding all seven peptides under review—including BPC-157, KPV, TB-500, MOTS-C, Emidylotide, DSIP, Cmax, and Epitalion—to the 503A compounding bulks list. The ruling effectively bans their use in human compounding outside of research settings.

The peptides targeted had marketed uses for ulcerative colitis, wound healing, obesity, osteoporosis, and opioid withdrawal. Many have been sold through gray-market channels online, often with questionable quality—products lacking active ingredients, contaminated, or inert altogether.

The backdrop matters: these peptides were already technically banned but enforcement had been lax. The FDA's review process offered a potential off-ramp, a chance for the gray market to legitimize into pharmacy compounding. That door is now closed.

The real casualty is timing. Legitimate biotech companies betting on FDA approval and moving into the space in anticipation of a favorable ruling now face a regulatory dead end. Unless RFK Kennedy overrides the decision, the peptides remain off-limits for human use.

The newly constituted pharmacy compounding advisory committee meets in July. That meeting will be the next pressure point for the industry, but the structural damage is done. The gray market persists, but the legitimate path forward has collapsed.